The adverse jury verdict introduces material downside uncertainty—potential multi-billion dollar liability could pressure Takeda's cash flows and balance sheet. Monitor for entry of judgment, size of the recorded provision in revised FY2025 results, and any settlement or appeal timelines. Takeda no longer markets AMITIZA, limiting operational read-through, but the financial overhang is substantial.
Price Chart
Executive Summary
A U.S. federal jury returned a verdict against Takeda in the AMITIZA (lubiprostone) antitrust litigation, awarding plaintiffs USD 884,943,990 in single damages. Damages awarded to wholesalers and individual retailers will automatically treble upon judgment, creating a potential total liability in the billions. Takeda will pursue post-trial motions and appeal, and expects to record a provision revising FY2025 financial results, though FY2026 guidance is not expected to be materially impacted except for adjusted free cash flow.
Key Facts
- Jury verdict returned May 18, 2026 in U.S. District Court for Massachusetts in AMITIZA antitrust litigation.
- Plaintiffs awarded USD 884,943,990 in single damages.
- Wholesaler class damages of USD 474,897,965 and individual retailer damages of USD 346,837,646 will be automatically trebled upon entry of judgment.
- End payor class damages subject to further proceedings before judgment.
- Takeda plans to vigorously pursue post-trial motions and appeal.
- Takeda will record a provision in FY2025 financial statements as a subsequent event and revise FY2025 results.
- Takeda expects no material impact on FY2026 financial forecast or Management Guidance, except for adjusted free cash flow.
- Takeda no longer sells or markets AMITIZA as of March 31, 2024.
Financial Impact
Initial single damages of USD 884,943,990; automatic trebling of ~USD 821.7M (wholesaler + retailer portions) implies over ~USD 2.5B in those portions alone before end-payor adjustments; total potential liability could exceed $3B.
Risk Factors
- Total liability could exceed $3B once trebled and end-payor damages are added.
- Takeda's appeal may not succeed; legal process could take years.
- Revised FY2025 financials and potential negative free cash flow impact in FY2026.
- Credit rating downgrade risk if liability materially exceeds expectations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001395064-26-000149 |
| Document: 0001395064-26-000149-index-headers.html | 0001395064-26-000149 |
| Document: 0001395064-26-000149-index.html | 0001395064-26-000149 |
| Document: 0001395064-26-000149.txt | 0001395064-26-000149 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 9, 2026 20w ago | 6-K | $31.30 $32.48 | ▲ +3.77% | ▲ +1.97% | $41.22 (+31.69%) |
Jun 5, 2026 20w ago | 6-K | $30.47 $34.28 | ▼ −12.50% | ▼ −11.93% | $41.22 (−35.28%) |
Jun 5, 2026 20w ago | 6-K | $30.47 $34.28 | ▼ −12.50% | ▼ −11.93% | $41.22 (−35.28%) |
Jun 1, 2026 21w ago | 6-K | $30.47 $30.47 | · 0.00% | ▲ +2.75% | $41.22 (+35.28%) |
May 26, 2026 22w ago | 6-K | $32.10 $30.47 | ▼ −5.08% | ▼ −6.29% | $41.22 (+28.41%) |
May 26, 2026 22w ago | 6-K | $32.10 $30.47 | ▼ −5.08% | ▼ −6.29% | $41.22 (+28.41%) |
May 26, 2026 22w ago | 6-K | $32.10 $30.47 | ▼ −5.08% | ▼ −6.29% | $41.22 (+28.41%) |
May 26, 2026 22w ago | 6-K | $32.10 $30.47 | ▲ +5.08% | ▲ +6.29% | $41.22 (−28.41%) |
May 19, 2026 23w ago | 6-K | $32.26 $32.10 | ▲ +0.50% | ▲ +2.79% | $41.22 (−27.77%) |
May 13, 2026 23w ago | 6-K | $32.68 $32.26 | ▼ −1.29% | ▼ −0.13% | $41.22 (+26.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers